Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
Alzheimer's disease affects millions of people around the world. Currently, there are no
treatments that prevent or slow the disease. Like other neurodegenerative diseases …
treatments that prevent or slow the disease. Like other neurodegenerative diseases …
Multiplicity of cerebrospinal fluid functions: New challenges in health and disease
This review integrates eight aspects of cerebrospinal fluid (CSF) circulatory dynamics:
formation rate, pressure, flow, volume, turnover rate, composition, recycling and …
formation rate, pressure, flow, volume, turnover rate, composition, recycling and …
Blood-based protein biomarkers for diagnosis of Alzheimer disease
Objective To identify plasma biomarkers for the diagnosis of Alzheimer disease (AD). Design
Baseline plasma screening of 151 multiplexed analytes combined with targeted biomarker …
Baseline plasma screening of 151 multiplexed analytes combined with targeted biomarker …
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders
Biomarkers are needed to assist in the diagnosis and medical management of various
neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD) …
neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD) …
A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease
O Carrette, I Demalte, A Scherl… - PROTEOMICS …, 2003 - Wiley Online Library
The diagnosis of Alzheimer's disease (AD), the most common form of dementia in the
general population, usually relies upon the presence of typical clinical features and …
general population, usually relies upon the presence of typical clinical features and …
Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease
By comparing the cerebrospinal fluid (CSF) proteome between Alzheimer's disease (AD)
patients and controls, it may be possible to identify proteins that play a role in the disease …
patients and controls, it may be possible to identify proteins that play a role in the disease …
Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis
R Craig-Schapiro, M Kuhn, C **ong, EH Pickering… - PloS one, 2011 - journals.plos.org
Background Clinicopathological studies suggest that Alzheimer's disease (AD) pathology
begins∼ 10–15 years before the resulting cognitive impairment draws medical attention …
begins∼ 10–15 years before the resulting cognitive impairment draws medical attention …
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases
The therapeutic imperative for Alzheimer disease (AD) and Parkinson disease (PD) calls for
discovery and validation of biomarkers. Increased cerebrospinal fluid (CSF) τ and …
discovery and validation of biomarkers. Increased cerebrospinal fluid (CSF) τ and …
Brain and behavior changes in 12-month-old Tg2576 and nontransgenic mice exposed to anesthetics
SL Bianchi, T Tran, CL Liu, S Lin, Y Li, JM Keller… - Neurobiology of …, 2008 - Elsevier
Inhaled anesthetics have been shown to increase the aggregation of amyloid beta in vitro
through the stabilization of intermediate toxic oligomers, which are thought to contribute to …
through the stabilization of intermediate toxic oligomers, which are thought to contribute to …
Biomarkers of Alzheimer's disease
R Craig-Schapiro, AM Fagan, DM Holtzman - Neurobiology of disease, 2009 - Elsevier
Although a battery of neuropsychological tests is often used in making a clinical diagnosis of
Alzheimer's disease (AD), definitive diagnosis still relies on pathological evaluation at …
Alzheimer's disease (AD), definitive diagnosis still relies on pathological evaluation at …